136 related articles for article (PubMed ID: 25319103)
1. Short-chain glycoceramides promote intracellular mitoxantrone delivery from novel nanoliposomes into breast cancer cells.
Pedrosa LR; Ten Hagen TL; Süss R; van Hell A; Eggermont AM; Verheij M; Koning GA
Pharm Res; 2015 Apr; 32(4):1354-67. PubMed ID: 25319103
[TBL] [Abstract][Full Text] [Related]
2. Plasma membrane targeting by short chain sphingolipids inserted in liposomes improves anti-tumor activity of mitoxantrone in an orthotopic breast carcinoma xenograft model.
Cordeiro Pedrosa LR; van Tellingen O; Soullié T; Seynhaeve AL; Eggermont AM; Ten Hagen TL; Verheij M; Koning GA
Eur J Pharm Biopharm; 2015 Aug; 94():207-19. PubMed ID: 25982691
[TBL] [Abstract][Full Text] [Related]
3. Improving intracellular doxorubicin delivery through nanoliposomes equipped with selective tumor cell membrane permeabilizing short-chain sphingolipids.
Pedrosa LR; van Hell A; Süss R; van Blitterswijk WJ; Seynhaeve AL; van Cappellen WA; Eggermont AM; ten Hagen TL; Verheij M; Koning GA
Pharm Res; 2013 Jul; 30(7):1883-95. PubMed ID: 23666266
[TBL] [Abstract][Full Text] [Related]
4. Mitoxantrone- and Folate-TPGS2k Conjugate Hybrid Micellar Aggregates To Circumvent Toxicity and Enhance Efficiency for Breast Cancer Therapy.
Guissi NE; Li H; Xu Y; Semcheddine F; Chen M; Su Z; Ping Q
Mol Pharm; 2017 Apr; 14(4):1082-1094. PubMed ID: 28191959
[TBL] [Abstract][Full Text] [Related]
5. Cholesterol sulfate-mediated ion-pairing facilitates the self-nanoassembly of hydrophilic cationic mitoxantrone.
Zhang J; Fang H; Dai Y; Li Y; Li L; Zuo S; Liu T; Sun Y; Shi X; He Z; Sun J; Sun B
J Colloid Interface Sci; 2024 Sep; 669():731-739. PubMed ID: 38735255
[TBL] [Abstract][Full Text] [Related]
6. Quantitative and qualitative effect of gH625 on the nanoliposome-mediated delivery of mitoxantrone anticancer drug to HeLa cells.
Perillo E; Allard-Vannier E; Falanga A; Stiuso P; Vitiello MT; Galdiero M; Galdiero S; Chourpa I
Int J Pharm; 2015 Jul; 488(1-2):59-66. PubMed ID: 25891256
[TBL] [Abstract][Full Text] [Related]
7. Nanostructured lipid-carrageenan hybrid carriers (NLCCs) for controlled delivery of mitoxantrone hydrochloride to enhance anticancer activity bypassing the BCRP-mediated efflux.
Ling G; Zhang T; Zhang P; Sun J; He Z
Drug Dev Ind Pharm; 2016 Aug; 42(8):1351-9. PubMed ID: 26754913
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, distribution and anti-tumor efficacy of liposomal mitoxantrone modified with a luteinizing hormone-releasing hormone receptor-specific peptide.
Zhang L; Ren Y; Wang Y; He Y; Feng W; Song C
Int J Nanomedicine; 2018; 13():1097-1105. PubMed ID: 29520138
[TBL] [Abstract][Full Text] [Related]
9. Solid lipid nanoparticles of mitoxantrone for local injection against breast cancer and its lymph node metastases.
Lu B; Xiong SB; Yang H; Yin XD; Chao RB
Eur J Pharm Sci; 2006 May; 28(1-2):86-95. PubMed ID: 16472996
[TBL] [Abstract][Full Text] [Related]
10. Treatment Efficiency of Free and Nanoparticle-Loaded Mitoxantrone for Magnetic Drug Targeting in Multicellular Tumor Spheroids.
Hornung A; Poettler M; Friedrich RP; Zaloga J; Unterweger H; Lyer S; Nowak J; Odenbach S; Alexiou C; Janko C
Molecules; 2015 Sep; 20(10):18016-30. PubMed ID: 26437393
[TBL] [Abstract][Full Text] [Related]
11. Mitoxantrone-loaded chitosan/hyaluronate polyelectrolyte nanoparticles decorated with amphiphilic PEG derivates for long-circulating effect.
Wang J; Asghar S; Jin X; Chen Z; Huang L; Ping Q; Zong L; Xiao Y
Colloids Surf B Biointerfaces; 2018 Nov; 171():468-477. PubMed ID: 30077147
[TBL] [Abstract][Full Text] [Related]
12. Magnetically modified-mitoxantrone mesoporous organosilica drugs: an emergent multimodal nanochemotherapy for breast cancer.
Romaní-Cubells E; Martínez-Erro S; Morales V; Chocarro-Calvo A; García-Martínez JM; Sanz R; García-Jiménez C; García-Muñoz RA
J Nanobiotechnology; 2024 May; 22(1):249. PubMed ID: 38745193
[TBL] [Abstract][Full Text] [Related]
13. [Tumor cell targetability of folate receptor-mediated mitoxantrone albumin nanoparticles].
Zhang LK; Hou SX; Mao SJ; Wei DP; Song XR
Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Jan; 37(1):77-9. PubMed ID: 16468648
[TBL] [Abstract][Full Text] [Related]
14. Improved safety, pharmacokinetics and therapeutic efficacy profiles of a novel liposomal formulation of mitoxantrone.
Gokhale PC; Pei J; Zhang C; Ahmad I; Rahman A; Kasid U
Anticancer Res; 2001; 21(5):3313-21. PubMed ID: 11848489
[TBL] [Abstract][Full Text] [Related]
15. Cationic drug-derived nanoparticles for multifunctional delivery of anticancer siRNA.
Chang RS; Suh MS; Kim S; Shim G; Lee S; Han SS; Lee KE; Jeon H; Choi HG; Choi Y; Kim CW; Oh YK
Biomaterials; 2011 Dec; 32(36):9785-95. PubMed ID: 21937102
[TBL] [Abstract][Full Text] [Related]
16. Sterically stabilized polymeric nanoparticles with a combinatorial approach for multi drug resistant cancer: in vitro and in vivo investigations.
Zafar S; Negi LM; Verma AK; Kumar V; Tyagi A; Singh P; Iqbal Z; Talegaonkar S
Int J Pharm; 2014 Dec; 477(1-2):454-68. PubMed ID: 25445525
[TBL] [Abstract][Full Text] [Related]
17. Reduced dose-limiting toxicity of intraperitoneal mitoxantrone chemotherapy using cardiolipin-based anionic liposomes.
Chang RS; Kim J; Lee HY; Han SE; Na J; Kim K; Kwon IC; Kim YB; Oh YK
Nanomedicine; 2010 Dec; 6(6):769-76. PubMed ID: 20570638
[TBL] [Abstract][Full Text] [Related]
18. Treatment of experimental brain metastasis with MTO-liposomes: impact of fluidity and LRP-targeting on the therapeutic result.
Orthmann A; Zeisig R; Süss R; Lorenz D; Lemm M; Fichtner I
Pharm Res; 2012 Jul; 29(7):1949-59. PubMed ID: 22399388
[TBL] [Abstract][Full Text] [Related]
19. Tobacco mosaic virus delivery of mitoxantrone for cancer therapy.
Lin RD; Steinmetz NF
Nanoscale; 2018 Aug; 10(34):16307-16313. PubMed ID: 30129956
[TBL] [Abstract][Full Text] [Related]
20. Preparation, characterization, and in vivo evaluation of mitoxantrone-loaded, folate-conjugated albumin nanoparticles.
Zhang LK; Hou SX; Zhang JQ; Hu WJ; Wang CY
Arch Pharm Res; 2010 Aug; 33(8):1193-8. PubMed ID: 20803122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
